Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs leading to Discontinuation;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Vaccination or Until Resolution;Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination or Until Resolution;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by Enzyme-linked Immunosorbent Assay (ELISA) 28 Days After Vaccination

Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs leading to Discontinuation;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Vaccination or Until Resolution;Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination or Until Resolution;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by Enzyme-linked Immunosorbent Assay (ELISA) 28 Days After Vaccination

None

Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs leading to Discontinuation;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Vaccination or Until Resolution;Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination or Until Resolution;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by Enzyme-linked Immunosorbent Assay (ELISA) 28 Days After Vaccination

Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs leading to Discontinuation;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Vaccination or Until Resolution;Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination or Until Resolution;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by Enzyme-linked Immunosorbent Assay (ELISA) 28 Days After Vaccination

Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs leading to Discontinuation;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each vaccination or Until Resolution;Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination or Until Resolution;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by ELISA 14 Days After the Second Vaccination;Serological Response to Vaccination as Measured by Enzyme-linked Immunosorbent Assay (ELISA) 28 Days After the First Vaccination

Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs leading to Discontinuation;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each vaccination or Until Resolution;Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination or Until Resolution;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by ELISA 14 Days After the Second Vaccination;Serological Response to Vaccination as Measured by Enzyme-linked Immunosorbent Assay (ELISA) 28 Days After the First Vaccination

Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs leading to Discontinuation;Number of Participants with Antibody Geometric Mean Concentration (GMC) 28 Days After the First Vaccination;Number of Participants with Antibody GMC 14 Days After the Second Vaccination;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each vaccination or Until Resolution;Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination or Until Resolution;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by ELISA 14 Days After the Second Vaccination;Serological Response to Vaccination as Measured by Enzyme-linked Immunosorbent Assay (ELISA) 28 Days After the First Vaccination

Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with AEs leading to Discontinuation;Number of Participants with Antibody Geometric Mean Concentration (GMC) 28 Days After the First Vaccination;Number of Participants with Antibody GMC 14 Days After the Second Vaccination;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Each vaccination or Until Resolution;Number of Participants with Solicited Systemic AEs for 7 Days After Each Vaccination or Until Resolution;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by ELISA 14 Days After the Second Vaccination;Serological Response to Vaccination as Measured by Enzyme-linked Immunosorbent Assay (ELISA) 28 Days After the First Vaccination

Number of Participants with Antibody Geometric Mean Concentration (GMC) 28 Days After First Vaccination;Number of Participants with Antibody GMC 28 Days After Second Vaccination;Number of Participants with MAAEs leading to Discontinuation;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs);Number of Participants with Solicited Systemic AEs;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by ELISA 28 Days After Second Vaccination;Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination

Number of Participants with Antibody Geometric Mean Concentration (GMC) 28 Days After First Vaccination;Number of Participants with Antibody GMC 28 Days After Second Vaccination;Number of Participants with MAAEs leading to Discontinuation;Number of Participants with Medically-attended Adverse Events (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local Adverse Events (AEs);Number of Participants with Solicited Systemic AEs;Number of Participants with Unsolicited AEs;Serological Response to Vaccination as Measured by ELISA 28 Days After Second Vaccination;Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination

Groups 1-10: Number of Participants with Antibody Geometric Mean Concentration (GMC) 28 Days After First Vaccination;Groups 1-10: Number of Participants with MAAEs leading to Discontinuation;Groups 1-10: Number of Participants with Medically-attended Adverse Events (MAAEs);Groups 1-10: Number of Participants with Serious Adverse Events (SAEs);Groups 1-10: Number of Participants with Solicited Local Adverse Events (AEs);Groups 1-10: Number of Participants with Solicited Systemic AEs;Groups 1-10: Number of Participants with Unsolicited AEs;Groups 1-10: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination;Groups 8-10: Number of Participants with Antibody GMC 28 Days After Second Vaccination;Groups 8-10: Serological Response to Vaccination as Measured by ELISA 28 Days After Second Vaccination

Groups 1-10: Number of Participants with Antibody Geometric Mean Concentration (GMC) 28 Days After First Vaccination;Groups 1-10: Number of Participants with MAAEs leading to Discontinuation;Groups 1-10: Number of Participants with Medically-attended Adverse Events (MAAEs);Groups 1-10: Number of Participants with Serious Adverse Events (SAEs);Groups 1-10: Number of Participants with Solicited Local Adverse Events (AEs);Groups 1-10: Number of Participants with Solicited Systemic AEs;Groups 1-10: Number of Participants with Unsolicited AEs;Groups 1-10: Serological Response to Vaccination as Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination;Groups 8-10: Number of Participants with Antibody GMC 28 Days After Second Vaccination;Groups 8-10: Serological Response to Vaccination as Measured by ELISA 28 Days After Second Vaccination